Blood Glycan Biomarkers in Women With Stage IV Breast Cancer
NCT ID: NCT00897962
Last Updated: 2018-12-26
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
163 participants
OBSERVATIONAL
2006-09-30
2016-01-12
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
PURPOSE: This research study is looking at blood glycan biomarkers in women with stage IV breast cancer.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
* To profile serum glycan biomarkers in women with metastatic stage IV breast cancer, healthy controls, and patients with noncancer medical illness.
* To determine whether serial serum glycan biomarkers correlate with response of metastatic disease to treatment.
OUTLINE: This is a multicenter study.
Blood is collected from patients with metastatic breast cancer, patients with noncancerous illness, and healthy volunteers. Samples are analyzed for serum glycan biomarkers by matrix-assisted laser desorption/ionization (MALDI) and Fourier transform ion-cyclotron resonance mass spectrometry (FT ICR MS) methods.
Blood samples are collected every 3 months for up to 18 months from patients with metastatic breast cancer. Patients without cancer have a single sample collected.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Keywords
Explore important study keywords that can help with search, categorization, and topic discovery.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
OTHER
OTHER
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Metastatic Breast Cancer
Patients with metastatic breast cancer receiving treatment with chemotherapy, endocrine therapy or targeted therapy
Metastatic Breast Cancer
Blood samples will be drawn every 3 months, for up to 18 months.
Non-cancer medical illness
Patients with non-cancer medical condition
Non-cancer medical illness
One blood draw (2 teaspoons)
Healthy Controls
Healthy patients being seen for an annual exam
Healthy Controls
One blood draw (2 teaspoons)
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Healthy Controls
One blood draw (2 teaspoons)
Metastatic Breast Cancer
Blood samples will be drawn every 3 months, for up to 18 months.
Non-cancer medical illness
One blood draw (2 teaspoons)
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Patient or participant at the Women's Health Clinic, the Internal Medicine Clinic, or at the UC Davis Cancer Center, meeting 1 of the following criteria:
* Diagnosis of stage IV metastatic breast cancer, receiving active treatment with chemotherapy, endocrine therapy, or targeted therapy
* Patients/participants without cancer
* Healthy control being seen for annual exams, meeting the following criteria:
* No chronic disease
* Not on regular prescribed medications
* Patient without cancer being seen in the Internal Medicine Clinic
* Hormone receptor status not specified
PATIENT CHARACTERISTICS:
* Menopausal status not specified
* Not pregnant or breast feeding
* No other active cancer
PRIOR CONCURRENT THERAPY:
* See Disease Characteristics
18 Years
FEMALE
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
University of California, Davis
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Helen K. Chew, MD
Role: STUDY_CHAIR
University of California, Davis
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
University of California Davis Cancer Center
Sacramento, California, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
UCD-186
Identifier Type: -
Identifier Source: secondary_id
UCD-200614601
Identifier Type: -
Identifier Source: secondary_id
CDR0000583066
Identifier Type: OTHER
Identifier Source: secondary_id
234870
Identifier Type: -
Identifier Source: org_study_id